Basel, February 18th, 2026, FimmCyte AG ("FimmCyte"), a pioneering Swiss biotech developing targeted immunotherapies for chronic fibro-inflammatory diseases, announces a strategic research...
Results
The FimmCyte Insights
FimmCyte Recognized in the 2024 and 2025 TOP 100 Swiss Startup Award
FimmCyte proudly claims a spot in the prestigious TOP 100 Swiss Startup Award for two consecutive years, ranking #28 in 2024 (4th in the biotech sector) and #54 in 2025. Selected by a panel of 100...
FimmCyte Announces Strategic Collaboration with Gedeon Richter in Endometriosis
Basel, February 18th, 2026, FimmCyte AG ("FimmCyte"), a pioneering Swiss biotech developing targeted immunotherapies...
FimmCyte Recognized in the 2024 and 2025 TOP 100 Swiss Startup Award
FimmCyte proudly claims a spot in the prestigious TOP 100 Swiss Startup Award for two consecutive years, ranking #28...
FimmCyte obtains CHF 1 million from the UZH Life Sciences Fund
FimmCyte, a pioneering women's health biotech, announces an investment of 1 million CHF as a convertible loan from the...
FimmCyte welcomes Dr. Markus Kalousek as Chairperson of the Board of Directors
FimmCyte AG, a pioneering women's health biotech, announces the appointment of Dr. Markus Kalousek as chairperson of...